ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Synlogic Scores Major Funding

by Lisa M. Jarvis
February 22, 2016 | APPEARED IN VOLUME 94, ISSUE 8

Synlogic has raised $40 million in its second large financing round, which was led by OrbiMed HealthCare Fund Management and included founding investors Atlas Venture and New Enterprise Associates. Synlogic, which uses synthetic biology to push gut bacteria to sense and repair disease, will use the funds to support two drugs in development. The company hopes to put treatments for urea cycle disorder and phenylketonuria, both rare metabolic diseases, into clinical studies in early 2017. With this latest round, it has brought in $70 million in funding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment